Accelerating SARS-CoV-2 Immunotherapy Speed To Clinic With Pre-Made Process Liquids

A clinical-stage biotherapeutics company developing a COVID-19 immunotherapy faced difficulties in scaling up its manufacturing operations due to limited resources. To solve this issue, the company outsourced the production of ten different buffers to a chemical supplier. The company's previous chemical supplier presented problems with delayed communications specifically regarding lead time issues and any small volume requests from the supplier. To overcome these problems, the company collaborated with Thermo Fisher Scientific, who supplied pre-made process liquids for use in manufacturing. This partnership resulted in significant annual cost savings and a 36% reduction in lead times, allowing the biotherapeutics company to concentrate on its primary goal of speeding up SARS-CoV-2 immunotherapy development.